Motor Neuron Disease & Paraproteinemia
Neurol 37:335-337, Rudnicki,S.,et al, 1987
Clinicopath Conf
Castleman's Disease, Synd of Polyneuropathy, Organomegally, Endocrinopathy, Monoclonal Gammopathy, &, Skin CPOEM Synd),NEJM 316:606-618,1987., 1987
Mononeuritis Multiplex in Waldenstrom's Macroglobulinemia
Ann Neurol 22:268-272, Lamarca,J.,et al, 1987
Peripheral Neuropathy in Macroglobulinemia:Incidence & Antigen-Specificity of M Proteins
Neurol 37:1506-1514, Nobile-Orazio,E.,et al, 1987
Peripheral Neuropathy Associated with Monoclonal IgM Autoantibody
Ann Neurol 22:764-767, Steck,A.J.,et al, 1987
Proximal Motor Neuropathy, Dermato-Endocrine Syndrome, & IgGk Paraproteinemia
Arch Neurol 43:845-848, Berkovic,S.F.,et al, 1986
Motor Neuron Disease & Plasma Cell Dyscrasia
Neurol 36:1429-1436, Shy,M.E.,et al, 1986
Chronic Idiopathic Ataxic Neuropathy
Ann Neurol 19:545-554, Dalakas,M.C., 1986
Gammopathy with Proximal Motor Axonopathy Simulating Motor Neuron Disease
Neurol 36:273-276, Parry,G.J.,et al, 1986
Treatment of Peripheral Neuropathies
JNNP 48:1193-1207, Hallett,M.,et al, 1985
Polymyositis Associated with Monoclonal Gammopathy
Lancet 2:1183-1186, Kiprov,D.D.,et al, 1984
Osteosclerotic Myeloma & Peripheral Neuropathy
Neurol 33:202-210, Kelly,J.J.,et al, 1983
Polyneuropathy in Nonmalignant IgM Plasma Cell Dyscrasia:A Morphological Study
Ann Neurol 14:43-54, Nemni,R.,et al, 1983
Treatment of Polyneuropathy in Waldenstrom's Macroglobulinemia:Role of Paraproteinemia & Immunologic Studies
Neurol 33:1406-1410, Dalakas,M.C.,et al, 1983
Peripheral Neuropathy with IgM Kappa Monoclonal Immunoglobulin Directed Against Myelin-Associated Glycoprotein
Neurol 33:1397-1405, Melmed,C.,et al, 1983
Amyotrophic Lateral Sclerosis & Paraproteinemia
Neurol 32:896-898, Krieger,C.,et al, 1982
Polyneuropathy with Monoclonal Gammopathy:Studies of 11 Patients
Ann Neurol 10:45-52, Dalakas,M.C.,et al, 1981
Plasma-Cell Dyscrasia & Peripheral Neuropathy With A Monoclonal Antibody To Peripheral-Nerve Myelin
NEJM 303:618-621, Latov,N.,et al, 1980
Clinical Insights Into CASPR1 and CASPR1/Contactin1 Com-lex Autoimmune Nodopathies
Neurol 106:e214403, Paramasivan,N.K.,et al, 2026
Polymyalgia Rheumatica
NEJM 394:1097-1109, Dejaco,C.,et al, 2026
A 35-Year-Old Man with Recurrent Asymmetric Lumbosacral and Cervical Plexopathy
Neurol 106:e214910, Tayade,K.S., et al, 2026
A 28-Year-Old Man with Seizures and Thalamic Lesions
Neurol 106:e218065, Santos-Rojo,A.B.,et al, 2026
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
A 66-Year-Old Man with Chronic Orthostatic Hypotension
Neurol 105:e214294, Lenka,A. & Vernino,S, 2025
A 30-Year-Old Female Patient with Multiple Sclerosis Presenting with Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia
Neurol 105:e214429, Trentadue,T.,et al, 2025
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome
Neurol 105:e213848, Cabral,A.,et al, 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Lecanemab, Looking Before We Leap
Neurol 101:661-665, Burke,J.F.,et al, 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
A 60-Year Old Man with Asymmetric Weakness and Persistent Fever
Neurol 100:530-536, Zheng,Y.,et al, 2023
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023